Challenges and solutions in sexual health among women after treatment for malignant neoplasms of the female reproductive system

Sexual dysfunction is one of the most common and underestimated issues observed in women undergone treatment for malignant neoplasms of the female reproductive system. Here, we review current data on the impact of surgical treatment, radiation therapy, and chemotherapy on patients’ sexual health, including symptoms such as vaginal dryness, dyspareunia, decreased sexual desire, and dissatisfaction with intimate life. Special attention is paid to the importance of screening for sexual dysfunction at all stages – from diagnosis to long-term survival. We discuss modern approaches to managing sexual dysfunction, including hormonal and non-hormonal therapies, vaginal moisturizers and lubricants, use of vaginal dilators, pelvic floor physical therapy, psychosocial counseling, and local anesthetic application. The effectiveness of multidisciplinary programs implemented in specialized sexual health clinics is highlighted, along with the growing importance of telemedicine and online resources for patients living in areas with limited access to specialized care. The article also addresses sexual health inequity access to services among marginalized groups, including individuals with low socioeconomic status, residents of rural areas, and members of sexual and gender minority communities. The need to increase awareness among healthcare professionals, integrate sexual health screening into routine oncology practice, and develop individualized rehabilitation programs to improve the quality of women’s life after gynecologic cancer treatment is emphasized.

1. Shakhzadova A.O., Starinsky V.V., Lisichnikova I.V. Cancer care to the population of Russia in 2022. [Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2022 godu]. Sibirskij onkologicheskij zhurnal. 2023;22(5):5–13. (In Russ). https://doi.org/10.21294/1814-4861-2023-22-5-5-13.

2. Avksentyev N.A., Sisigina N.N., Frolov M.Yu., Makarov A.S. Analysis impact of using novel antineoplastic drugs on cancer mortality in Russia. [Ocenka vklada primeneniya sovremennyh protivoopuholevyh lekarstvennyh preparatov v dostizhenie celej federal'nogo proekta po bor'be s onkozabolevaniyami]. Voprosy onkologii. 2021;67(6):768–76. https://doi.org/10.37469/0507-3758-2021-67-6-768-776.

3. Siegel R.L., Kratzer T.B., Giaquinto A.N. et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10–45. https://doi.org/10.3322/caac.21871.

4. Sopfe J., Pettigrew J., Afghahi A. et al. Interventions to improve sexual health in women living with and surviving cancer: review and recommendations. Cancers (Basel). 2021;13(13):3153. https://doi.org/10.3390/cancers13133153.

5. Solopova A.G., Sandzhieva L.N., Galkin V.N. et al. Restoration of sexual function after surgical treatment for endometrial cancer. [Vosstanovlenie seksual'noj funkcii posle hirurgicheskogo lecheniya raka endometriya]. Reabilitologiya. 2024;2(2):177–85. (In Russ.). https://doi.org/10.17749/2949-5873/rehabil.2024.11.

6. Jing L., Zhang C., Li W. et al. Incidence and severity of sexual dysfunction among women with breast cancer: a meta-analysis based on female sexual function index. Support Care Cancer. 2019;27(4):1171–80. https://doi.org/10.1007/s00520-019-04667-7.

7. Kedrova A.G. Preserving vaginal health after treatment for gynecological malignancies. [Vozmozhnosti sohraneniya zdorov'ya vlagalishcha posle lecheniya opuholej zhenskoj reproduktivnoj sistemy]. Opuholi zhenskoj reproduktivnoj sistemy. 2022;18(4):121–6. (In Russ.). https://doi.org/10.17650/1994-4098-2022-18-4-121-126.

8. Kondrateva K.O., Semiglazova T.YU. Kasparov B.S.Women's sexuality after breast cancer treatment. [Osobennosti seksual'nosti zhenshchin posle lecheniya raka molochnoj zhelezy]. Voprosy onkologii. 2023;69(1):108–14. https://doi.org/10.37469/0507-3758-2023-69-1-108-114.

9. Robison K., Kulkarni A., Dizon D.S. Sexual health in women affected by gynecologic or breast cancer. Obstet Gynecol. 2024;143(4):499–514. https://doi.org/10.1097/AOG.0000000000005506.

10. Kanorskii S.G. Sexual dysfunction in men and women with arterial hypertension. South [Seksual'naya disfunkciya u muzhchin i zhenshchin s arterial'noj gipertenziej]. Yuzhno-Rossijskij zhurnal terapevticheskoj praktiki. 2024;5(2):17–28. (In Russ.). https://doi.org/10.21886/2712-8156-2024-5-2-17-28.

11. Sungur M.Z., Gündüz A. A comparison of DSM-IV-TR and DSM-5 definitions for sexual dysfunctions: critiques and challenges. J Sex Med. 2014;11(2):364–73. https://doi.org/10.1111/jsm.12379.

12. Reed M.A. Female sexual dysfunction. Clin Plast Surg. 2022;49(4):495–504. https://doi.org/10.1016/j.cps.2022.06.009.

13. Fausto D.Y., Martins J.B.B, da Silveira J. et al. Association between menopausal symptoms, sexual function, and sexual activity – a cross-sectional study. Prz Menopauzalny. 2023;22(4):220–6. https://doi.org/10.5114/pm.2023.133570.

14. Mundhra R., Bahadur A., Khoiwal K. et al. Female sexuality across the menopausal age group: a cross sectional study. Eur J Obstet Gynecol Reprod Biol X. 2024;21:100287. https://doi.org/10.1016/j.eurox.2024.100287.

15. Ahmed M.R., Shaaban M.M., Meky H.K. Assessment of sexually related personal distress accompanying premenopausal sexual dysfunction with an Arabic version of the Female Sexual Distress Scale. Int J Gynaecol Obstet. 2017;139(1):65–70. https://doi.org/10.1002/ijgo.12255.

16. Carter J., Lacchetti C., Andersen B.L. et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol. 2018;36(5):492–511. https://doi.org/10.1200/JCO.2017.75.8995.

17. Wiggins D.L., Wood R., Granai C.O., Dizon D.S. Sex, intimacy, and the gynecologic oncologists: survey results of the New England Association of Gynecologic Oncologists (NEAGO). J Psychosoc Oncol. 2007;25(4):61–70. https://doi.org/10.1300/J077v25n04_04.

18. Kennedy V., Abramsohn E., Makelarski J. et al. Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol. 2015;137(1):119–24. https://doi.org/10.1016/j.ygyno.2015.01.451.

19. Sanft T., Day A., Ansbaugh S. et al. NCCN Guidelines® Insights: Survivorship, Version 1.2023. J Natl Compr Canc Netw. 2023;21(8):792–803. https://doi.org/10.6004/jnccn.2023.0041.

20. Sopfe J., Marsh R., Ziniel S.I. et al. Evaluation of the v2.0 brief profiles for sexual function and satisfaction PROMIS in adolescent and young adult childhood cancer survivors. J Adolesc Young Adult Oncol. 2021;10(4):418–24. https://doi.org/10.1089/jayao.2020.0166.

21. Polter E.J., Kohli N., Rosser B.R.S. et al. Creation and psychometric validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients – the Restore-2 Study. J Sex Med. 2022;19(3):529–40. https://doi.org/10.1016/j.jsxm.2021.12.012.

22. Greimel E., Nagele E., Lanceley A. et al. EORTC Quality of Life Group. Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22). Eur J Cancer. 2021;154:235–45. https://doi.org/10.1016/j.ejca.2021.06.003.

23. Idrisova L.E, Solopova A.G, Makatsariya A.D et al. The possibilities of restoring sexual function in women after breast cancer treatment. [Vozmozhnosti vosstanovleniya seksual'noj funkcii u zhenshchin posle lecheniya raka molochnoj zhelezy]. Vrach. 2018;29(4):64–7. https://doi.org/10.29296/258773052018-04-13.

24. Lindau S.T., Gavrilova N., Anderson D. Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. Gynecol Oncol. 2007;106(2):413–8. https://doi.org/10.1016/j.ygyno.2007.05.017.

25. Green M.S., Naumann R.W., Elliot M. et al. Sexual dysfunction following vulvectomy. Gynecol Oncol. 2000;77(1):73–7. https://doi.org/10.1006/gyno.2000.5745.

26. Podzolkova N.M., Koloda Iu.A., Nikitina T.I. Laparoscopic hysterectomy: effect on sexual function. [Laparoskopicheskaya gisterektomiya: vliyanie na seksual'nuyu funkciyu]. Problemy reprodukcii. 2012;(6):60–2. (In Russ.).

27. Pak R., Sadykova T., Kaidarova D. et al. The life quality and sexual function of women underwent radical hysterectomy. Asian Pac J Cancer Prev. 2021;22(2):581–9. https://doi.org/10.31557/APJCP.2021.22.2.581.

28. Pieterse Q.D., Maas C.P., ter Kuile M.M. et al. An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. Int J Gynecol Cancer. 2006;16(3):1119–29. https://doi.org/10.1111/j.1525-1438.2006.00461.x.

29. Maas C.P., ter Kuile M.M., Laan E. et al. Objective assessment of sexual arousal in women with a history of hysterectomy. BJOG. 2004;111(5):456–62. https://doi.org/10.1111/j.1471-0528.2004.00104.x.

30. Plante M., Kwon J.S., Ferguson S. et al. Simple versus radical hysterectomy in women with low-risk cervical cancer. N Engl J Med. 2024;390(9):819–29. https://doi.org/10.1056/NEJMoa2308900.

31. Mukhin A.A., Vazhenin A.V., Saevets V.V ., Taratonov A.V. Surgical treatment of locally advanced vulvar cancer. [Hirurgicheskoe lechenie mestno-rasprostranennogo raka vul'vy]. Zlokachestvennye opuholi. 2020;10(3):20–5. (In Russ.). https://doi.org/10.18027/2224-5057-2020-10-3-20-25.

32. Flynn K.E., Carter J., Lin L. et al. Assessment of vulvar discomfort with sexual activity among women in the United States. Am J Obstet Gynecol. 2017;216(4):391.e1–391.e8. https://doi.org/10.1016/j.ajog.2016.12.006.

33. Likes W.M., Stegbauer C., Tillmanns T., Pruett J. Correlates of sexual function following vulvar excision. Gynecol Oncol. 2007;105(3):600–3. https://doi.org/10.1016/j.ygyno.2007.01.027.

34. Barlow E.L., Hacker N.F., Hussain R., Parmenter G. Sexuality and body image following treatment for early-stage vulvar cancer: a qualitative study. J Adv Nurs. 2014;70(8):1856–66. https://doi.org/10.1111/jan.12346.

35. Günther V., Malchow .B, Schubert M. et al. Impact of radical operative treatment on the quality of life in women with vulvar cancer--a retrospective study. Eur J Surg Oncol. 2014;40(7):875–82. https://doi.org/10.1016/j.ejso.2014.03.027.

36. Sibirskaya E.V., Nikiforova P.O., Rabadanova N.R. Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review). [Pervichnaya citoreduktivnaya hirurgiya s posleduyushchej himioterapiej v sravnenii s neoad"yuvantnoj himioterapiej s posleduyushchej citoredukciej v kachestve lecheniya III i IV stadij raka yaichnika (obzor literatury)]. Opuholi zhenskoj reproduktivnoj sistemy. 2024;20(1):124–30. (In Russ.). https://doi.org/10.17650/1994-4098-2024-20-1-124-130.

37. Hughes C.L., Wall L.L., Creasman W.T. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol Oncol. 1991;40(1):42–5. https://doi.org/10.1016/0090-8258(91)90083-h.

38. Blinov D.V., Solopova A.G., Achkasov E.E., et al. Strengthening rehabilitation for patients with ovarian tumors: current approaches and future directions. [Organizaciya reabilitacii pacientok s opuholyami yaichnikov: sovremennye podhody i budushchie napravleniya]. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(2):303–16. (In Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.196.

39. Yoshida K., Yamazaki H., Nakamura S. et al. Longitudinal analysis of late vaginal mucosal reactions after high-dose-rate brachytherapy in patients with gynecological cancer. Anticancer Res. 2014;34(8):4433–8.

40. Charatsi D., Vanakara P., Evaggelopoulou E. et al. Vaginal dilator use to promote sexual wellbeing after radiotherapy in gynecological cancer survivors. Medicine (Baltimore). 2022;101(4):e28705. https://doi.org/10.1097/MD.0000000000028705.

41. Rovirosa Á., Ascaso C., Herreros A. et al. A new short daily brachytherapy schedule in postoperative endometrial carcinoma. Preliminary results. Brachytherapy. 2017;16(1):147–52. https://doi.org/10.1016/j.brachy.2016.10.001.

42. Hill-Kayser C., Yorke E., Jackson A. et al. Effects of radiation therapy on the female reproductive tract in childhood cancer survivors: a PENTEC comprehensive Review. Int J Radiat Oncol Biol Phys. 2024;119(2):588–609. https://doi.org/10.1016/j.ijrobp.2023.08.013.

43. Derks M., van Lonkhuijzen L.R., Bakker R.M. et al. Long-term morbidity and quality of life in cervical cancer survivors: a multicenter comparison between surgery and radiotherapy as primary treatment. Int J Gynecol Cancer. 2017;27(2):350–6. https://doi.org/10.1097/IGC.0000000000000880.

44. Maiorino M.I., Chiodini P., Bellastella G. et al. Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index. Endocrine. 2016;54(2):329–41. https://doi.org/10.1007/s12020-015-0812-6.

45. Liavaag A.H., Dørum A., Bjøro T. et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol. 2008;108(2):348–54. https://doi.org/10.1016/j.ygyno.2007.10.009.

46. Wu X., Wu L., Han J. et al. Evaluation of the sexual quality of life and sexual function of cervical cancer survivors after cancer treatment: a retrospective trial. Arch Gynecol Obstet. 2021;304(4):999–1006. https://doi.org/10.1007/s00404-021-06005-x.

47. Kulkarni A., Sun G., Manuppelli S. et al. Sexual health and function among patients receiving systemic therapy for primary gynecologic cancers. Gynecol Oncol. 2022;165(2):323–29. https://doi.org/10.1016/j.ygyno.2022.03.008.

48. Whicker M., Black J., Altwerger G. et al. Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. Am J Obstet Gynecol. 2017;217(4):395–403. https://doi.org/10.1016/j.ajog.2017.04.012.

49. Robison K., Kulkarni A., Dizon D.S. Sexual health in women affected by gynecologic or breast cancer. Obstet Gynecol. 2024;143(4):499–514. https://doi.org/10.1097/AOG.0000000000005506.

50. Rowland J.H., Meyerowitz B.E., Crespi C.M. et al. Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention. Breast Cancer Res Treat. 2009;118(1):99–111. https://doi.org/10.1007/s10549-009-0398-x.

51. Kalaitzi C., Papadopoulos V.P., Michas K. et al. Combined brief psychosexual intervention after mastectomy: effects on sexuality, body image, and psychological well-being. J Surg Oncol. 2007;96(3):235–40. https://doi.org/10.1002/jso.20811.

52. Andreeva E.N., Sheremetyeva E.V. The problem of female sexuality. [Problema zhenskoj seksual'nosti]. Problemy reprodukcii. 2019;25(3):40–50. (In Russ.). https://doi.org/10.17116/repro20192503140.

53. Ratner E.S., Foran K.A., Schwartz P.E., Minkin M.J. Sexuality and intimacy after gynecological cancer. Maturitas. 2010;66(1):23–6. https://doi.org/10.1016/j.maturitas.2010.01.015.

54. Simon J.A., Thorp J., Millheiser L. Flibanserin for premenopausal hypoactive sexual desire Disorder: pooled analysis of clinical trials. J Womens Health (Larchmt). 2019;28(6):769–77. https://doi.org/10.1089/jwh.2018.7516.

55. Kamrul-Hasan A.B.M., Hannan M.A., Alam M.S. et al. Role of flibanserin in managing hypoactive sexual desire disorder in women: a systematic review and meta-analysis. Medicine (Baltimore). 2024;103(25):e38592. https://doi.org/10.1097/MD.0000000000038592.

56. Simon J.A., Kingsberg S.A., Shumel B. et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633–40. https://doi.org/10.1097/GME.0000000000000134.

57. Goldfarb S.B., Carter J., Arkema A. et al. Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy. J Clin Oncol. 2023;41(16):12015. https://doi.org/10.1200/JCO.2023.41.16_suppl.12015.

58. Shaukat A., Mujeeb A., Shahnoor S. et al. "Veozah (Fezolinetant): a promising non-hormonal treatment for vasomotor symptoms in menopause". Health Sci Rep. 2023;6(10):e1610. https://doi.org/10.1002/hsr2.1610.

59. Rafaelyan I.V., Balan V.E., Kovaleva L.A. Phytoestrogens: what is known today [Fitoestrogeny: chto izvestno na segodnyashnij den]. Akusherstvo i ginekologia. 2012;(5):4–9. (In Russ.).

60. Balan V.E., Rafalian I.V., Levkovich E.A. et al. Specific features of long-term use of phytoestrogens to treat patients with climacteric syndrome. [Osobennosti dlitel'nogo primeneniya fitoestrogenov dlya lecheniya pacientok s klimaktericheskim sindromom]. Rossijskij vestnik akushera-ginekologa. 2013;13(5):58–62. (In Russ.).

61. Goetsch M.F., Lim J.Y., Caughey A.B. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394–400. https://doi.org/10.1200/JCO.2014.60.7366.

62. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–94. https://doi.org/10.1097/GME.0000000000002028.

63. Babaeva N.A., Yureneva S.V., Aleshikova O.I. et al. Possibilities of using hormone therapy in patients treated for malignant neoplasms of the vulva, vagina, and uterine cervix and body. [Vozmozhnosti ispol'zovaniya gormonal'noj terapii u bol'nyh, perenesshih lechenie po povodu zlokachestvennyh novoobrazovanij vul'vy, vlagalishcha, shejki i tela matki. Onkologiya]. Zhurnal imeni P.A. Gercena. 2023;12(1):45–52. (In Russ.). https://doi.org/10.17116/onkolog20231201145.

64. Nazarenko T.A., Parokonnaia A.A., Sharipova N.Yu. The use of aromatase inhibitors in art in women with breast cancer. [Primenenie ingibitorov aromatazy u bol'nyh rakom molochnoj zhelezy v programmah vspomogatel'nyh reproduktivnyh tekhnologij]. Problemy reprodukcii. 2012;(2):72–6. (In Russ.).

65. Shlyakhto E.V., Sukhikh G.T., Serov V.N. et al. Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia. [Rossijskie kriterii priemlemosti naznacheniya menopauzal'noj gormonal'noj terapii pacientkam s serdechno-sosudistymi i metabolicheskimi zabolevaniyami. Soglasitel'nyj dokument RKO, ROAG, RAE, EAT, RAF]. Problemy endokrinologii. 2023;69(5):115–36. (In Russ.). https://doi.org/10.14341/probl13394.

66. Santen R.J. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121–34. https://doi.org/10.3109/13697137.2014.947254.

67. Manson J.E., Chlebowski R.T., Stefanick M.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353–68. https://doi.org/10.1001/jama.2013.278040.

68. Yakushevskaya O.V., Yureneva S.V., Khabas G.N., Protasova A.E. Menopausal hormone therapy and cervical cancer: a current view of the problem. [Menopauzal'naya gormonal'naya terapiya i rak shejki matki: sovremennyj vzglyad na problem]. Akusherstvo i ginekologia. 2017;(11):148–53. (In Russ.). https://doi.org/10.18565/aig.2017.11.148-153.

69. Yakushevskaya O.V., Averkova V.G., Yureneva S.V. History of cancer and induced menopause: help – cannot be reconciled. [Otyagoshchennyj onkologicheskij anamnez i klimaktericheskie rasstrojstva: pomoch' nel'zya mirit'sya]. Meditsinskiy sovet. 2025;(4):151–9. (In Russ.). https://doi.org/10.21518/ms2025-169.

70. Barakat R.R., Bundy B.N., Spirtos N.M. et al Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(4):587–92. https://doi.org/10.1200/JCO.2005.02.8464.

71. Pergialiotis V., Pitsouni E., Prodromidou A. et al. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause. 2016;23(3):335–42. https://doi.org/10.1097/GME.0000000000000508.

72. Beishembaev A.М. Features of treatment rare forms of stromal cell ovarian tumors. [Osobennosti lecheniya redkih form stromal'no-kletochnyh opuholej yaichnikov: seriya klinicheskih nablyudenij]. Tazovaya hirurgiya i onkologiya. 2021;11(1):28–34. (In Russ.). https://doi.org/10.17650/2686-9594-2021-11-1-28-34.

73. Achimaș-Cadariu P.A., Păun D.L., Pașca A. Impact of hormone replacement therapy on the overall survival and progression free survival of ovarian cancer patients: a systematic review and meta-analysis. Cancers (Basel). 2023;15(2):356. https://doi.org/10.3390/cancers15020356.

74. Abu-Rustum N.R., Yashar C.M., Arend R. et al. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. J Natl Compr Canc Netw. 2023;21(12):1224–33. https://doi.org/10.6004/jnccn.2023.0062.

75. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol. 1987;26(2):169–77. https://doi.org/10.1016/0090-8258(87)90270-8.

76. Lacey J.V., Brinton L.A., Barnes W.A. et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol. 2000;77(1):149–54. https://doi.org/10.1006/gyno.2000.5731.

77. Lushnikova P.A., Sukhikh E.S., Izhevsky P.V. et al. Modern techniques for cervical cancer radiotherapy. [Sovremennye metody luchevoj terapii raka shejki matki]. Kreativnaya hirurgiya i onkologiya. 2021;11(1):58–67. (In Russ.). https://doi.org/10.24060/2076-3093-2021-11-1-58-67.

78. Dikke G.B., Ostromenskiy V.V., Shcherbatykh E.Yu. Vaginal dilaters in the prevention and treatment of stenosis and vaginal pain syndromes. [Vlagalishchnye dilatatory v profilaktike i lechenii stenoza i bolevyh sindromov vlagalishcha]. Akusherstvo i ginekologiya. 2023;(12):181–8. https://doi.org/10.18565/aig.2023.296.

79. Quinn B.A., Deng X., Sullivan S.A. et al. Change in vaginal length and sexual function in women who undergo surgery ± radiation therapy for endometrial cancer. Brachytherapy. 2023;22(3):334–42. https://doi.org/10.1016/j.brachy.2023.01.005.

80. Liu M., Juravic M., Mazza G., Krychman M.L. Vaginal dilators: issues and answers. Sex Med Rev. 2021;9(2):212–20. https://doi.org/10.1016/j.sxmr.2019.11.005.

81. Barbera L., Zwaal C., Elterman D. et al.; Interventions to Address Sexual Problems in People with Cancer Guideline Development Group. Interventions to address sexual problems in people with cancer. Curr Oncol. 2017;24(3):192–200. https://doi.org/10.3747/co.24.3583.

82. Apolikhina I.A., Rodionov V.V., Seialova A.S. et al. Pelvic floor muscle training in women with a history of breast cancer. [Trenirovka myshc tazovogo dna u zhenshchin, perenesshih rak molochnyh zhelez]. Ginekologiya. 2019;21(1):19–22. https://doi.org/10.26442/20795696.2019.1.190229.

83. Cyr M.P., Dostie R., Camden C. et al. Acceptability of multimodal pelvic floor physical therapy to treat dyspareunia after gynecological malignancies: a qualitative study of women's views and experiences. Int Urogynecol J. 2023;34(5):1061–73. https://doi.org/10.1007/s00192-022-05304-4.

84. Cyr M.P., Dostie R., Camden C. et al. Improvements following multimodal pelvic floor physical therapy in gynecological cancer survivors suffering from pain during sexual intercourse: results from a one-year follow-up mixed-method study. PLoS One. 2022;17(1):e0262844. https://doi.org/10.1371/journal.pone.0262844.

85. Chernova N.I., Dolya O.V., Frigo N.V., Zadorozhnaya I.S. Moisturizers in the management of patients with complaints of dryness in the genital area. [Uvlazhnyayushchie sredstva pri vedenii pacientok s zhalobami na suhost' v oblasti genitalij]. Akusherstvo i ginekologiya. 2024;(8):134–40. https://doi.org/10.18565/aig.2024.198.

86. Edwards D., Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–61. https://doi.org/10.3109/13697137.2015.1124259.

87. Juraskova I., Jarvis S., Mok K. et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J Sex Med. 2013;10(10):2549–58. https://doi.org/10.1111/jsm.12156.

88. Stenyaeva N.N., Sattarova V.V., Pashkevich K.I. et al. Vaginal lubricants: efficacy, tolerability, safety and functionality. [Vaginal'nye lyubrikanty: effektivnost', perenosimost', bezopasnost' i funkcional'nost']. Akusherstvo i ginekologiya. 2023;(8):203–10. https://doi.org/10.18565/aig.2023.179.

89. Herbenick D., Reece M., Hensel D. et al. Association of lubricant use with women's sexual pleasure, sexual satisfaction, and genital symptoms: a prospective daily diary study. J Sex Med. 2011;8(1):202–12. https://doi.org/10.1111/j.1743-6109.2010.02067.x.

90. Pérez-López F.R., Phillips N., Vieira-Baptista P. et al. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease. Gynecol Endocrinol. 2021;37(8):746–2. https://doi.org/10.1080/09513590.2021.1943346.

91. Loseva N.V., Yaroslavtseva I.V. Peculiarities of psychological counseling of women with reproductive dysfunction. [Osobennosti psihologicheskogo konsul'tirovaniya zhenshchin s narusheniem reproduktivnoj funkcii]. Acta Biomedica Scientifica. 2014;(4):96–9. (In Russ.).

92. Samushia M.A. Mental disorders in patients with female reproductive system malignancies: a review of literature. [Psihicheskie rasstrojstva u pacientok so zlokachestvennymi opuholyami organov zhenskoj reproduktivnoj sistemy: obzor literatury]. Opuholi zhenskoj reproduktivnoj sistemy. 2011;(1):86–95. (In Russ.) https://doi.org/10.17650/1994-4098-2011-0-1-216-241.

93. Sandzhieva L.N., Solopova A.G., Blinov D.V. et al. Personalized comprehensive rehabilitation program after surgical treatment of endometrial cancer: results of a prospective randomized comparative study. [Personificirovannaya programma kompleksnoj reabilitacii posle hirurgicheskogo lecheniya raka endometriya: rezul'taty prospektivnogo randomizirovannogo sravnitel'nogo issledovaniya]. Obstetrics, Gynecology and Reproduction. 2022;16(2):143–57. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.318.

94. Tyuvina N.A., Balabanova V.V., Voronina E.O. The differential diagnosis and treatment of depressive disorders in climacteric transition. [Depressii u zhenshchin, manifestiruyushchie v period klimakteriya]. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2017;117(3):22–7. (In Russ.). https://doi.org/10.17116/jnevro20171173122-27.